脑室内阿替普酶与自发性脑出血及脑室内出血患者实质血肿体积的关系
本研究为脑室内出血溶栓加速溶解血肿(Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage)3期随机临床试验的事后探索性分析,纳入454例自发性脑出血合并脑室内出血患者,随机接受脑室内阿替普酶(230例)或生理盐水(224例)经脑室外引流管给药。阿替普酶组实质血肿体积平均缩小1.8 mL,生理盐水组缩小0.4 mL(P<.001);多因素线性回归中阿替普酶与实质血肿体积变化相关(每1 mL变化β=1.20,95%CI 0.79-1.62,P<.001)。但实质血肿体积变化与6个月改良Rankin量表评分>3分(OR 0.97,95%CI 0.87-1.10,P=.64)及死亡率(OR 0.97,95%CI 0.99-1.08,P=.59)均无关联。作者认为脑室内溶栓与实质血肿小幅缩小相关,但未转化为功能结局或死亡率改善。
要点
- 脑室内阿替普酶组实质血肿体积平均缩小1.8 mL,生理盐水组缩小0.4 mL(P<.001)。
- 多因素线性回归中,阿替普酶与实质血肿体积变化相关(每1 mL变化β=1.20,95%CI 0.79-1.62,P<.001)。
- 实质血肿体积变化与6个月改良Rankin量表评分>3分无关联(OR 0.97,95%CI 0.87-1.10,P=.64)。
- 实质血肿体积变化与6个月死亡率无关联(OR 0.97,95%CI 0.99-1.08,P=.59)。
- 亚组分析(基线脑室内出血体积、入院脑出血体积、脑出血部位)结果相似。
适用人群与场景
- 自发性脑出血合并脑室内出血患者,随机接受脑室内阿替普酶或生理盐水经脑室外引流管给药;原发性脑室内出血患者被排除。
- 数据来自2009年9月1日至2015年1月31日入组的Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage 3期随机临床试验。
研究设计与关键结果
- 研究类型:3期随机临床试验的事后探索性分析(队列研究),盲法评估结局;共纳入454例患者(男性254例,55.9%;平均[SD]年龄59[11]岁),阿替普酶组230例(50.7%),生理盐水组224例(49.3%)。
- 主要终点:阿替普酶组实质血肿体积平均(SD)缩小1.8(0.2)mL,生理盐水组缩小0.4(0.1)mL(P<.001)。
- 未调整分析中,阿替普酶与实质血肿体积变化相关(每1 mL变化β=1.37,95%CI 0.92-1.81,P<.001);多因素线性回归调整人口学特征、稳定性脑出血和脑室内出血体积、脑出血部位及首次研究药物给药时间后,每1 mL变化β=1.20(95%CI 0.79-1.62,P<.001)。
- 次要终点:实质血肿体积变化与6个月改良Rankin量表评分>3分无关联(OR 0.97,95%CI 0.87-1.10,P=.64);与6个月死亡率无关联(OR 0.97,95%CI 0.99-1.08,P=.59)。
- 亚组分析(基线脑室内出血体积、入院脑出血体积、脑出血部位)结果相似。
证据类型、等级与局限
- 证据类型:3期随机临床试验的事后探索性分析(队列研究),盲法评估结局。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脑室内阿替普酶用于脑室内出血量大的患者与实质血肿体积小幅缩小相关,但这一关联未转化为功能结局或死亡率改善。
- 作者建议,应在中等至大量脑出血合并脑室内出血的患者中检验脑室内溶栓,尤其是丘脑部位出血。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Intraventricular thrombolysis reduces intraventricular hemorrhage (IVH) volume in patients with spontaneous intracerebral hemorrhage (ICH), but it is unclear if a similar association with parenchymal ICH volume exists.
OBJECTIVE: To evaluate the association between intraventricular alteplase use and ICH volume as well as the association between a change in parenchymal ICH volume and long-term functional outcomes.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a post hoc exploratory analysis of data from the Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage phase 3 randomized clinical trial with blinded outcome assessments. Between September 1, 2009, and January 31, 2015, patients with ICH and IVH were randomized to receive either intraventricular alteplase or normal saline via an external ventricular drain. Participants with primary IVH were excluded. Data analyses were performed between January 1 and June 30, 2021.
EXPOSURE: Randomization to receive intraventricular alteplase.
MAIN OUTCOMES AND MEASURES: The primary outcome was the change in parenchymal ICH volume between the hematoma stability and end-of-treatment computed tomography scans. Secondary outcomes were a modified Rankin Scale score higher than 3 and mortality, both of which were assessed at 6 months. The association between alteplase and change in parenchymal ICH volume was assessed using multiple linear regression, whereas the associations between change in parenchymal ICH volume and 6-month outcomes were assessed using multiple logistic regression. Prespecified subgroup analyses were performed for baseline IVH volume, admission ICH volume, and ICH location.
RESULTS: A total of 454 patients (254 men [55.9%]; mean [SD] age, 59 [11] years) were included in the study. Of these patients, 230 (50.7%) were randomized to receive alteplase and 224 (49.3%) to receive normal saline. The alteplase group had a greater mean (SD) reduction in parenchymal ICH volume compared with the saline group (1.8 [0.2] mL vs 0.4 [0.1] mL; P < .001). In the primary analysis, alteplase use was associated with a change in the parenchymal ICH volume in the unadjusted analysis per 1-mL change (β, 1.37; 95% CI, 0.92-1.81; P < .001) and in multivariable linear regression analysis that was adjusted for demographic characteristics, stability ICH and IVH volumes, ICH location, and time to first dose of study drug per 1-mL change (β, 1.20; 95% CI, 0.79-1.62; P < .001). In the secondary analyses, no association was found between change in parenchymal ICH volume and poor outcome (odds ratio [OR], 0.97; 95% CI 0.87-1.10; P = .64) or mortality (OR, 0.97; 95% CI 0.99-1.08; P = .59). Similar results were observed in the subgroup analyses.
CONCLUSIONS AND RELEVANCE: This study found that intraventricular alteplase use in patients with a large IVH was associated with a small reduction in parenchymal ICH volume, but this association did not translate into improved functional outcomes or mortality. Intraventricular thrombolysis should be examined in patients with moderate to large ICH with IVH, especially in a thalamic location.
参考来源
- Witsch J, Roh DJ, Avadhani R, et al. Association Between Intraventricular Alteplase Use and Parenchymal Hematoma Volume in Patients With Spontaneous Intracerebral Hemorrhage and Intraventricular Hemorrhage. JAMA Netw Open. 2021. PMID: 34860246. doi:10.1001/jamanetworkopen.2021.35773
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。